

## Industry News (Jul 2023 to Dec 2023)

Viola Huang<sup>1</sup>

<sup>1</sup>ISoOR Insight Team

### **HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company**

July 18, 2023

To improve efficiency, respond quickly to market and customer demands, be more flexible, adapt to emerging industry trends, and accelerate global market expansion, Hubrecht Organoid Technology (HUB) is officially transitioning from a foundation to a private enterprise. HUB, founded by Hans Clevers in the Netherlands in 2013, is also the world's earliest center for organoid research and development. The technological support behind it includes Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), and Utrecht University Medical Center. At the same time, HUB technology licenses have facilitated organoid business for companies such as Epistem, Cellesce, Crown Bioscience, STEMCELL Technologies and others. Robert Vries, CEO of HUB, commented on the shift, "We are confident that this shift will provide us with the necessary tools and resources to deliver more value to our customers and partners." This transformation also allows the HUB to unlock more potential with greater autonomy and flexibility.

### **Successful Conclusion of the International Society of Organoid Research's First Annual Meeting**

August 7-8, 2023

From August 7 to 8, 2023, the International Society of Organoid Research (ISoOR) held its inaugural annual meeting in Singapore. Hosted by ISoOR and co-organised by the Pharmacological Society (Singapore) and Scipolis, the conference was themed "Organoid: Accelerate Your Research."

The event focused on the entire spectrum of the organoid industry, from basic research to industrial advancement, and the ongoing development and challenges faced in clinical applications. Participants engaged in rich discussions and exchanges, and initiated global standards for organoid banks.

### **Three Organoid Group Standards Advance Human Liver and Biliary Organoid Research**

August 11, 2023

Tsinghua Changgeng Hospital led the release of three organoid group standards: "Human Hepatopoietic Progenitor Cell Organoid Construction, Quality Control and Preservation Operational Guidelines", "Human Hepatobiliary Tumor Cell Organoid Construction, Quality Control and Preservation Operational Guidelines", and "Human Biliary Epithelial Tissue Organoid Construction, Quality Control and Preservation Operational Guidelines" were approved by the Chinese Society of Research Hospitals for

official release.

### **Breakthrough in Automated Organoid Culture Technology**

August 15, 2023

A major breakthrough in automated organoid culture was achieved when BAB's bioprinter (BioAssembly™ platform) successfully replaced manual culture of tumor spheroids; this platform can also be used in conjunction with a high-content imaging system for advanced detection and analysis, offering the possibility of scaling up organoid production, culture, and improving consistency.

### **National Natural Science Foundation of China Announces Organoid Program Review Results**

September 4, 2023

National Natural Science Foundation of China issued a "notice on the results of the 2023 National Natural Science Foundation of China Centralized Acceptance of Application Project Evaluation", announced the specific funding projects, a number of organizations have announced the winning projects, as the "14th Five-Year Plan" priority areas for development, the number of organ-like projects to reach a new record high.

### **Roche's Genentech Acquires Herophilus**

September 11, 2023

Genentech, a Roche company, acquires the human organoid-based drug discovery platform of Herophilus, which develops neurological therapies for complex brain disorders, and which includes Orchard™, Orchestra™ and OrCA™ technologies.

### **Seraxis Announces \$50 Million in Financing for Diabetes Organoid Therapy**

September 21, 2023

Diabetes Organoid Therapy Funding Reaches \$50 Million: Seraxis, a company focused on diabetes organoid therapies, announced the closing of its second venture capital round, which brings the company's total equity investment to more than \$50 million, and the imminent filing of an IND application for SR-02, a novel pancreatic organoid manufactured from stem cell lines derived from human donor pancreas, its lead product, which is planned to enter clinical trials in 2024 alongside immunosuppressive therapies for the treatment of severe recurrent hypoglycemia in patients with severe recurrent hypoglycemia.

### **Novo Nordisk and Valo Health Develop New Therapies for Cardiometabolic Diseases**

September 28, 2023

Novo Nordisk and Valo Health jointly announced that they have entered into an agreement to discover and develop new therapies for cardiometabolic diseases based on Valo's Opal™ Computational Platform, which leverages real-world patient data, AI-enabled small molecule discovery, and the Biowire® human tissue modeling platform. Valo is licensed to develop Novo Nordisk's three preclinical drug programs in cardiovascular disease; Valo will receive upfront and potential near-term milestone payments totaling \$60 million and is eligible to receive milestone payments for up to 11 programs totaling up to \$2.7 billion.

### **Notice of Consultation on Technical Guidelines for Non-clinical Studies of Human Stem Cell Products**

October 7, 2023

In order to standardize and guide the non-clinical research and evaluation of human-derived stem cell products, CDE issued a notice on the public solicitation of opinions on the "Technical Guidelines for Non-clinical Research on Human-Derived Stem Cell Products (Solicitation Draft)", which clarifies the application of organoid technology to the guiding principles of the model for non-clinical research and evaluation of human-derived stem cell products.

### **Vivodyne's Lab Grown Human Tissue Platform Gets Real with \$38 Million Seed Financing**

November 23, 2023

Vivodyne has announced the closing of seed financing totaling \$38 million, led by KhoslaVentures with participation from KairosVentures, CSVentures, MBXCapital and BisonVentures. The funding will reportedly be used to advance Vivodyne's discovery pipeline and Clinical Prediction Artificial Intelligence (AI) platform, which identifies new therapeutic targets and predicts patient response to new drugs by testing them directly on human organ tissues cultured in the lab.